Short Communication

Some Biochemical Markers in Patients with Alzheimer’s Disease

Abstract

Background: Metal ions effect on homeostasis of Alzheimer’s disease (AD) patients. The aim of this study was to assess the metal ions (Iron, Zinc and Copper) and CBC in patients with AD in comparison with normal range.

Methods: The samples of study were 17 patients with AD in Tehran’s aging centers in 2015, selected as an access sample. Blood samples were analyzed in a pathobiology laboratory. Data were analyzed by one sample t-test.

Results: According to the normal range, provided by laboratory, there is a significant difference between zinc in patients with AD and normal reference interval (α=0.01). The comparison of CBC of the AD patients with normal group showed also some decreases

Conclusion: Zinc value in AD patients is significantly lower than normal range. It should be repeated by a larger sample size.

 

Khanahmadi M, Farhud DD, Malmir M (2015). Genetic in Alzheimer's disease-a narrative review article. Iran J Public Health, 44(7):892-901.

Squitti R, Lupoi D, Pasqualetti P, et al. (2002). Elevation of serum copper levels in Alz-heimer’s disease. Neurology, 59: 1153-61.

Markesbery WR (1997). Oxidative stress hy-pothesis in Alzheimer’s disease. Free Radic Biol Med, 23: 134-47.

Aly WW, Elsaid SMS, Wahba HMF (2013). Copper, zinc and iron serum levels in pa-tients with Alzheimer's disease. Life Sci J, 10(3): 2628-2632.

Bush AI, Pettingell WH, Multhaup G, et al. (1994). Rapid induction of Alzheimer Abeta amyloid formation by zinc. Science, 265:1464-67.

Hozumi I, Hasegawa T, Honda A, et al. (2011). Patterns of levels of biological metals in CSF differ among neurodegen-erative disease. J Neurol Sci, 303: 95-99.

Vural H, dermirin H, Kara Y, Eren I, Delbias N (2010). Alterations of plasma magnesium, copper, zinc, iron and sele-nium concentrations and some related erythrocyte antioxidant enzyme activities in patients with AD. J Trace Elem Med Biol, 24:169-173.

Ayton S, Lei P, Bush AI (2013). Metallostasis in AD. Free Radic. Free Radic Biol Med, 62:67-89.

Altamura S, Muckenthaler MU (2009). Iron toxicity in diseases of aging: AD, Parkin-son disease and atherosclerosis. J Alzhei-mer's Dis, 16: 879-895.

Miyata M, Smith JD (1996). Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxity by oxidative insults and beta-amiloid peptides. Nat Genet, 14: 55-61.

Cui L, Schoene NW, Zhu L, Fanzo JC, Al-shatwi A, Lei KY. (2002). Zinc depletion reduced Egr-1 and HNF-3beta expres-sion and apolipoprotein A-I promoterac-tivityinHepG2cells. Am J Physiol Cell Physiol, 283: C623–C630.

Xu H, Finkelstein DI, Adlard PA (2014). In-teractions of metals and apolipoprotein E in Alzheimer's disease. Front Aging Neuro-sci, 6: 121.

Bush AI, Multhaup G, Moir RD, et al. (1993). A novel zinc (II) binding site modulates the function of the βA4 amy-loid protein precursor of Alzheimer’s dis-ease. J Biol Chem, 268(22): 16109–16112.

Bush AI, Pettingell WH, De Paradis M, Tan-zi RE, Wasco W (1994). The amyloid β-protein precursor and its mammalian homologues. Evidence for a zinc-modulated heparin binding super family. J Biol Chem, 269(43): 26618–26621.

Rembach A, Hare DJ, Doecke JD, et al (2014). Decreased serum zinc is an effect of ageing and not alzheimer's disease. Metallomics, 6: 1216-1219.

Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM (2006). Human amyloid-β synthesis and clear-ance rates as measured in cerebrospinal fluid in vivo. Nat Med, 12(7): 856–861.

Multhaup G, Busha AI, Pollweina P, Masters CL (1994). Interaction between the zinc (II) and the heparin binding site of the Alzheimer’s disease βA4 amyloid precur-sor protein (APP). FEBS Letters, 355(2): 151–154.

Chow VW, Mattson MP, Wong PC, Gleichmann M (2010). An overview of APP processing enzymes and products. Neuromolecular Med, 12(1): 1–12.

Edwards DR, Handsley MM, Pennington CJ (2008). The ADAM metalloproteinas-es. Mol Aspects Med, 29(5): 258–289.

Files
IssueVol 45 No 10 (2016) QRcode
SectionShort Communication(s)
Keywords
Iron Copper Zinc Alzheimer's disease

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
KHANAHMADI M, D.FARHUD D, MALMIR M, ORANG S. Some Biochemical Markers in Patients with Alzheimer’s Disease. Iran J Public Health. 2016;45(10):1355-1358.